CPhI Show Daily Podcast Series - Valsynthese - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Show Daily Podcast Series - Valsynthese


Valsynthese - Mr. Helmut Zimmerman


Helmut Zimmermann
Commercial Director
Valsynthese

Add this Podcast feed to your media player



Valsynthese is a custom manufacturing organisation concentrating on hazardous and high energetic chemistry. Mr. Zimmermann introduces Valsynthese’s new capabilities in phosgenation, further expanding their tool-box of core competencies in highly energetic reactions. Mr. Zimmerman also delivers quality system updates as well as future plans for compliance beyond approval as API manufacturers in Europe, Asia, South America and Japan. Reducing environmental impact through investment in new recycling facilities is also discussed.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here